Participants who attended the meeting in a group photograph
Participants who attended the meeting in a group photo

Critical action needs to be taken now to address future human vaccine access challenge in Africa -Africa Civil Society Actors in the HIV Field can help fill existing gaps

By Morenike Oluwatoyin Folayan, Everest Okeakpu, Bartholomew Ibeh, Chukwunonso Ikeotuonye

The Africa Vaccine Manufacturing Initiative (AVMI) held its annual meeting at the Radisson hotel, Freetown, Sierra Leone on the 24th and 25th of September, 2018. The meeting had over 40 persons from Africa, Europe, America in attendance. Discussants at the meeting noted that vaccine manufacturing in Africa is critical especially at this time that more countries on the continent are graduating from GAVI. Nigeria recently asked for the extension of its graduation till 2028.

Sadly, there is no transition plan for countries who will graduate from GAVI on the continent that produces only 1% of its human vaccine needs. Vaccine manufacturing on the continent needs to be actively promoted. Actions to address the gap that will be created from Africa nations graduating from GAVI needs to be strategically planned now.Government action is critical for vaccine manufacturing. The process is capital intensive with limited potential for profit in the short term. Promoting public-private partnerships will be helpful. A lot more needs to be done on the continent to get the governments to do more than sign on to resolutions that promotes vaccine manufacture.

The Governments of Senegal, Ghana and Nigeria have been exemplary in this respect. The Senegalese government supports the continued production of yellow fever vaccine. The Ghanaian government in collaboration with Merck, Bosch and the German government are also working at developing a vaccine manufacturing plant in Ghana through the ASPIRx project, whilst the Nigerian government recently gave approval to a Joint Venture company, with the government, Biovaccines and May and Baker Pharmaceuticals PLC to reactivate vaccines manufacturing in the country.Sadly, Nigeria and South Africa had produced human vaccines – yellow fever, small pox – in the past. The poor focus on maintenance resulted in their failure to meet global standards for human vaccine production. There are continued concerns about the continent been able to produce quality vaccines. Participants were however certain about the competency to produce quality vaccine on the continent. However, we have to produce at a standard higher than that in the USA to regain public confidence, stated Simon Agwale the CEO of Innovative Biotech working towards the development of a HIV vaccine and the production of typhoid vaccines in Nigeria.

Government commitment to fund vaccine manufacturing is essential. This is a gap area which Civil Society working in the field of HIV can help. We do not need to start from the scratch noted Mrs Sybil Ossei-Agyeman-Yeboah, of the West Africa Health Organisation. We can harness the milestone the civil society working in the field of HIV had gained to fast-track advocacy for government support for vaccine manufacturing in Africa she expressed.

AVMI should serve and is poised to serve as the regional platform for coordinating vaccine development and manufacturing efforts in Africa. They should be setting the agenda, prioritizing the development of low cost technologies for vaccine manufacturing, and should be funding and supporting advocacy for vaccine development and manufacturing on the continent.This does not preclude the role of the Regional Economic Communities from facilitating vaccine manufacturing. The role they have played in harmonizing regulatory processes as seen in East Africa and ongoing in West Africa is of significant importance for vaccine manufacture.

There is prospect and an already large and growing vaccine market in Africa. Available data shows that the high birthrate in Africa exceeds its capacity to vaccinate. This has so far obscured the spirited efforts at attaining full vaccination and eradication of child diseases. Also, there is no influenza manufacturing efforts going on on the continent nor are there preparatory efforts to prepare for an influenza outbreaks that will likely occur.

There are evidences to show that Africa has the competency to develop vaccines. Biovac is exporting vaccine technology while Institute Pasture in Senegal is producing yellow fever vaccine. What the continent needs is capacity enhancement and not capacity building. ‘However, there is a gap in civil society engagement in this field’ Morenike Folayan, the Coordinator of the New HIV Vaccine and Microbicide Advocacy Society identified. ‘Civil Society organisations like the Vaccine Advocacy Resource Group and the WACIHealth are poised to take this advocacy forward’ she noted.